Skip to main content
Top
Published in: Diabetologia 6/2014

01-06-2014 | Article

Genome-wide association study of urinary albumin excretion rate in patients with type 1 diabetes

Authors: Niina Sandholm, Carol Forsblom, Ville-Petteri Mäkinen, Amy Jayne McKnight, Anne-May Österholm, Bing He, Valma Harjutsalo, Raija Lithovius, Daniel Gordin, Maija Parkkonen, Markku Saraheimo, Lena M. Thorn, Nina Tolonen, Johan Wadén, Jaakko Tuomilehto, Maria Lajer, Emma Ahlqvist, Anna Möllsten, M. Loredana Marcovecchio, Jason Cooper, David Dunger, Andrew D. Paterson, Gianpaolo Zerbini, Leif Groop, Lise Tarnow, Alexander P. Maxwell, Karl Tryggvason, Per-Henrik Groop, on behalf of The SUMMIT Consortium, on behalf of the FinnDiane Study Group

Published in: Diabetologia | Issue 6/2014

Login to get access

Abstract

Aims/hypothesis

An abnormal urinary albumin excretion rate (AER) is often the first clinically detectable manifestation of diabetic nephropathy. Our aim was to estimate the heritability and to detect genetic variation associated with elevated AER in patients with type 1 diabetes.

Methods

The discovery phase genome-wide association study (GWAS) included 1,925 patients with type 1 diabetes and with data on 24 h AER. AER was analysed as a continuous trait and the analysis was stratified by the use of antihypertensive medication. Signals with a p value <10−4 were followed up in 3,750 additional patients with type 1 diabetes from seven studies.

Results

The narrow-sense heritability, captured with our genotyping platform, was estimated to explain 27.3% of the total AER variability, and 37.6% after adjustment for covariates. In the discovery stage, five single nucleotide polymorphisms in the GLRA3 gene were strongly associated with albuminuria (p < 5 × 10−8). In the replication group, a nominally significant association (p = 0.035) was observed between albuminuria and rs1564939 in GLRA3, but this was in the opposite direction. Sequencing of the surrounding genetic region in 48 Finnish and 48 UK individuals supported the possibility that population-specific rare variants contribute to the synthetic association observed at the common variants in GLRA3. The strongest replication (p = 0.026) was obtained for rs2410601 between the PSD3 and SH2D4A genes. Pathway analysis highlighted natural killer cell mediated immunity processes.

Conclusions/interpretation

This study suggests novel pathways and molecular mechanisms for the pathogenesis of albuminuria in type 1 diabetes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Nathan DM, Zinman B, Cleary PA et al (2009) Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983–2005). Arch Intern Med 169:1307PubMedCentralPubMedCrossRef Nathan DM, Zinman B, Cleary PA et al (2009) Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983–2005). Arch Intern Med 169:1307PubMedCentralPubMedCrossRef
2.
go back to reference Caramori ML, Fioretto P, Mauer M (2006) Enhancing the predictive value of urinary albumin for diabetic nephropathy. J Am Soc Nephrol 17:339–352PubMedCrossRef Caramori ML, Fioretto P, Mauer M (2006) Enhancing the predictive value of urinary albumin for diabetic nephropathy. J Am Soc Nephrol 17:339–352PubMedCrossRef
3.
go back to reference Remuzzi G, Benigni A, Remuzzi A (2006) Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 116:288–296PubMedCentralPubMedCrossRef Remuzzi G, Benigni A, Remuzzi A (2006) Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 116:288–296PubMedCentralPubMedCrossRef
4.
go back to reference Groop PH, Thomas MC, Moran JL et al (2009) The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 58:1651PubMedCentralPubMedCrossRef Groop PH, Thomas MC, Moran JL et al (2009) The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 58:1651PubMedCentralPubMedCrossRef
5.
go back to reference Tarnow L, Groop PH, Hadjadj S et al (2008) European rational approach for the genetics of diabetic complications–EURAGEDIC: patient populations and strategy. Nephrol Dial Transplant 23:161–168PubMedCrossRef Tarnow L, Groop PH, Hadjadj S et al (2008) European rational approach for the genetics of diabetic complications–EURAGEDIC: patient populations and strategy. Nephrol Dial Transplant 23:161–168PubMedCrossRef
6.
go back to reference Parving HH, Smidt UM (1986) Hypotensive therapy reduces microvascular albumin leakage in insulin-dependent diabetic patients with nephropathy. Diabet Med 3:312–315PubMedCrossRef Parving HH, Smidt UM (1986) Hypotensive therapy reduces microvascular albumin leakage in insulin-dependent diabetic patients with nephropathy. Diabet Med 3:312–315PubMedCrossRef
7.
go back to reference Ritz E, Viberti GC, Ruilope LM et al (2010) Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia 53:49–57PubMedCentralPubMedCrossRef Ritz E, Viberti GC, Ruilope LM et al (2010) Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia 53:49–57PubMedCentralPubMedCrossRef
8.
go back to reference Forsblom CM, Kanninen T, Lehtovirta M, Saloranta C, Groop LC (1999) Heritability of albumin excretion rate in families of patients with type II diabetes. Diabetologia 42:1359–1366PubMedCrossRef Forsblom CM, Kanninen T, Lehtovirta M, Saloranta C, Groop LC (1999) Heritability of albumin excretion rate in families of patients with type II diabetes. Diabetologia 42:1359–1366PubMedCrossRef
9.
go back to reference Krolewski AS, Poznik GD, Placha G et al (2006) A genome-wide linkage scan for genes controlling variation in urinary albumin excretion in type II diabetes. Kidney Int 69:129–136PubMedCrossRef Krolewski AS, Poznik GD, Placha G et al (2006) A genome-wide linkage scan for genes controlling variation in urinary albumin excretion in type II diabetes. Kidney Int 69:129–136PubMedCrossRef
10.
go back to reference Quinn M, Angelico MC, Warram JH, Krolewski AS (1996) Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39:940–945PubMedCrossRef Quinn M, Angelico MC, Warram JH, Krolewski AS (1996) Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39:940–945PubMedCrossRef
11.
go back to reference Harjutsalo V, Katoh S, Sarti C, Tajima N, Tuomilehto J (2004) Population-based assessment of familial clustering of diabetic nephropathy in type 1 diabetes. Diabetes 53:2449–2454PubMedCrossRef Harjutsalo V, Katoh S, Sarti C, Tajima N, Tuomilehto J (2004) Population-based assessment of familial clustering of diabetic nephropathy in type 1 diabetes. Diabetes 53:2449–2454PubMedCrossRef
13.
go back to reference Fioretto P, Mauer M (2010) Diabetic nephropathy: diabetic nephropathy-challenges in pathologic classification. Nat Rev Nephrol 6:508–510PubMedCrossRef Fioretto P, Mauer M (2010) Diabetic nephropathy: diabetic nephropathy-challenges in pathologic classification. Nat Rev Nephrol 6:508–510PubMedCrossRef
14.
15.
go back to reference Pezzolesi MG, Poznik GD, Mychaleckyj JC et al (2009) Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes 58:1403–1410PubMedCentralPubMedCrossRef Pezzolesi MG, Poznik GD, Mychaleckyj JC et al (2009) Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes 58:1403–1410PubMedCentralPubMedCrossRef
16.
go back to reference Thorn LM, Forsblom C, Fagerudd J et al (2005) Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 28:2019–2024PubMedCrossRef Thorn LM, Forsblom C, Fagerudd J et al (2005) Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 28:2019–2024PubMedCrossRef
17.
go back to reference Del Bo R, Scarlato M, Ghezzi S et al (2006) VEGF gene variability and type 1 diabetes: evidence for a protective role. Immunogenetics 58:107–112PubMedCrossRef Del Bo R, Scarlato M, Ghezzi S et al (2006) VEGF gene variability and type 1 diabetes: evidence for a protective role. Immunogenetics 58:107–112PubMedCrossRef
18.
go back to reference Lindholm E, Agardh E, Tuomi T, Groop L, Agardh CD (2001) Classifying diabetes according to the new WHO clinical stages. Eur J Epidemiol 17:983–989PubMedCrossRef Lindholm E, Agardh E, Tuomi T, Groop L, Agardh CD (2001) Classifying diabetes according to the new WHO clinical stages. Eur J Epidemiol 17:983–989PubMedCrossRef
19.
go back to reference Mollsten A, Kockum I, Svensson M et al (2008) The effect of polymorphisms in the renin–angiotensin–aldosterone system on diabetic nephropathy risk. J Diabet Complicat 22:377–383CrossRef Mollsten A, Kockum I, Svensson M et al (2008) The effect of polymorphisms in the renin–angiotensin–aldosterone system on diabetic nephropathy risk. J Diabet Complicat 22:377–383CrossRef
20.
go back to reference Amin R, Widmer B, Prevost AT et al (2008) Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study. BMJ 336:697–701PubMedCentralPubMedCrossRef Amin R, Widmer B, Prevost AT et al (2008) Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study. BMJ 336:697–701PubMedCentralPubMedCrossRef
21.
go back to reference Marcovecchio ML, Dalton RN, Schwarze CP et al (2009) Ambulatory blood pressure measurements are related to albumin excretion and are predictive for risk of microalbuminuria in young people with type 1 diabetes. Diabetologia 52:1173–1181PubMedCrossRef Marcovecchio ML, Dalton RN, Schwarze CP et al (2009) Ambulatory blood pressure measurements are related to albumin excretion and are predictive for risk of microalbuminuria in young people with type 1 diabetes. Diabetologia 52:1173–1181PubMedCrossRef
22.
24.
go back to reference Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR (2010) MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 34:816–834PubMedCentralPubMedCrossRef Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR (2010) MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 34:816–834PubMedCentralPubMedCrossRef
25.
go back to reference Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38:904–909PubMedCrossRef Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38:904–909PubMedCrossRef
26.
go back to reference Purcell S, Neale B, Todd-Brown K et al (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81:559–575PubMedCentralPubMedCrossRef Purcell S, Neale B, Todd-Brown K et al (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81:559–575PubMedCentralPubMedCrossRef
30.
go back to reference Barrett JC (2009) Haploview: visualization and analysis of SNP genotype data. Cold Spring Harb Protoc 2009:pdb.ip71 Barrett JC (2009) Haploview: visualization and analysis of SNP genotype data. Cold Spring Harb Protoc 2009:pdb.ip71
31.
go back to reference NCBI Resource Coordinators (2013) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 41:D8–D20PubMedCentralCrossRef NCBI Resource Coordinators (2013) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 41:D8–D20PubMedCentralCrossRef
32.
go back to reference Segre AV, DIAGRAM Consortium, MAGIC investigators et al (2010) Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. PLoS Genet 6:e1001058PubMedCentralPubMedCrossRef Segre AV, DIAGRAM Consortium, MAGIC investigators et al (2010) Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. PLoS Genet 6:e1001058PubMedCentralPubMedCrossRef
33.
34.
go back to reference Anderson CA, Soranzo N, Zeggini E, Barrett JC (2011) Synthetic associations are unlikely to account for many common disease genome-wide association signals. PLoS Biol 9:e1000580PubMedCentralPubMedCrossRef Anderson CA, Soranzo N, Zeggini E, Barrett JC (2011) Synthetic associations are unlikely to account for many common disease genome-wide association signals. PLoS Biol 9:e1000580PubMedCentralPubMedCrossRef
35.
go back to reference Norio R (2003) Finnish Disease Heritage I: characteristics, causes, background. Hum Genet 112:441–456PubMed Norio R (2003) Finnish Disease Heritage I: characteristics, causes, background. Hum Genet 112:441–456PubMed
36.
go back to reference Norio R (2003) Finnish Disease Heritage II: population prehistory and genetic roots of Finns. Hum Genet 112:457–469PubMed Norio R (2003) Finnish Disease Heritage II: population prehistory and genetic roots of Finns. Hum Genet 112:457–469PubMed
37.
go back to reference Kingsmore SF, Suh D, Seldin MF (1994) Genetic mapping of the glycine receptor alpha 3 subunit on mouse chromosome 8. Mamm Genome 5:831–832PubMedCrossRef Kingsmore SF, Suh D, Seldin MF (1994) Genetic mapping of the glycine receptor alpha 3 subunit on mouse chromosome 8. Mamm Genome 5:831–832PubMedCrossRef
38.
go back to reference Li C, Liu C, Nissim I et al (2013) Regulation of glucagon secretion in normal and diabetic human islets by gamma-hydroxybutyrate and glycine. J Biol Chem 288:3938–3951PubMedCentralPubMedCrossRef Li C, Liu C, Nissim I et al (2013) Regulation of glucagon secretion in normal and diabetic human islets by gamma-hydroxybutyrate and glycine. J Biol Chem 288:3938–3951PubMedCentralPubMedCrossRef
39.
go back to reference den Eynden JV, Ali SS, Horwood N et al (2009) Glycine and glycine receptor signalling in non-neuronal cells. Front Mol Neurosci 2:9 den Eynden JV, Ali SS, Horwood N et al (2009) Glycine and glycine receptor signalling in non-neuronal cells. Front Mol Neurosci 2:9
40.
go back to reference Yin M, Zhong Z, Connor HD et al (2002) Protective effect of glycine on renal injury induced by ischemia-reperfusion in vivo. Am J Physiol Renal Physiol 282:F417–F423PubMedCrossRef Yin M, Zhong Z, Connor HD et al (2002) Protective effect of glycine on renal injury induced by ischemia-reperfusion in vivo. Am J Physiol Renal Physiol 282:F417–F423PubMedCrossRef
41.
go back to reference Woroniecka KI, Park AS, Mohtat D, Thomas DB, Pullman JM, Susztak K (2011) Transcriptome analysis of human diabetic kidney disease. Diabetes 60:2354–2369PubMedCentralPubMedCrossRef Woroniecka KI, Park AS, Mohtat D, Thomas DB, Pullman JM, Susztak K (2011) Transcriptome analysis of human diabetic kidney disease. Diabetes 60:2354–2369PubMedCentralPubMedCrossRef
42.
go back to reference Schmid H, Boucherot A, Yasuda Y et al (2006) Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 55:2993–3003PubMedCrossRef Schmid H, Boucherot A, Yasuda Y et al (2006) Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 55:2993–3003PubMedCrossRef
Metadata
Title
Genome-wide association study of urinary albumin excretion rate in patients with type 1 diabetes
Authors
Niina Sandholm
Carol Forsblom
Ville-Petteri Mäkinen
Amy Jayne McKnight
Anne-May Österholm
Bing He
Valma Harjutsalo
Raija Lithovius
Daniel Gordin
Maija Parkkonen
Markku Saraheimo
Lena M. Thorn
Nina Tolonen
Johan Wadén
Jaakko Tuomilehto
Maria Lajer
Emma Ahlqvist
Anna Möllsten
M. Loredana Marcovecchio
Jason Cooper
David Dunger
Andrew D. Paterson
Gianpaolo Zerbini
Leif Groop
Lise Tarnow
Alexander P. Maxwell
Karl Tryggvason
Per-Henrik Groop
on behalf of The SUMMIT Consortium
on behalf of the FinnDiane Study Group
Publication date
01-06-2014
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 6/2014
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-014-3202-3

Other articles of this Issue 6/2014

Diabetologia 6/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.